drugset / Trial / NCT00445692

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

NCT00445692

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies lenalidomide, dexamethasone, and clarithromycin in treating patients who have undergone stem cell transplant for multiple myeloma. Biological therapies, such as lenalidomide and clarithromycin, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with dexamethasone and clarithromycin may be an effective treatment for multiple myeloma.

Timeline

Start
2007-01-10
Primary completion
2017-04-24
Completion
2017-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule Oral
Subject Dexamethasone Small molecule Oral
Subject Lenalidomide Other / unclassified Oral

Indications